Daiwa Securities Group Inc. Boosts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Daiwa Securities Group Inc. boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 12.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,983 shares of the medical research company’s stock after purchasing an additional 3,908 shares during the period. Daiwa Securities Group Inc.’s holdings in IQVIA were worth $8,094,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in IQV. HighTower Advisors LLC raised its stake in shares of IQVIA by 2.4% in the first quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock valued at $1,168,000 after buying an additional 118 shares during the period. Prudential PLC bought a new stake in shares of IQVIA in the first quarter valued at $741,000. Baird Financial Group Inc. raised its stake in shares of IQVIA by 2.3% in the first quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock valued at $23,021,000 after buying an additional 2,201 shares during the period. Parkside Financial Bank & Trust raised its stake in shares of IQVIA by 59.0% in the first quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after buying an additional 144 shares during the period. Finally, Covestor Ltd raised its stake in shares of IQVIA by 82.2% during the 1st quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 250 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQV opened at $227.17 on Friday. The stock has a market capitalization of $41.23 billion, a P/E ratio of 31.16, a PEG ratio of 2.20 and a beta of 1.50. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The stock has a 50-day moving average price of $244.62 and a 200-day moving average price of $221.41. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. IQVIA’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.54 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on IQV shares. Truist Financial boosted their price objective on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. SVB Leerink started coverage on IQVIA in a research note on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective on the stock. Robert W. Baird boosted their price objective on IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. BTIG Research initiated coverage on IQVIA in a research note on Tuesday, February 13th. They set a “buy” rating and a $285.00 price objective on the stock. Finally, UBS Group upped their target price on IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

Insider Buying and Selling

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,285 shares of company stock worth $10,331,003. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.